Health Canada today released the October 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).
This issue includes an article on diabetes drugs known as incretin-based therapies and a possible association with pancreatic cancer. It also includes an article on the potential risk of liver injury associated with a steroid drug called methylprednisolone when it is injected intravenously (into a vein).
As well, it includes an article on a possible association between sorafenib, used to treat certain cancers, and a severe bone disease known as osteonecrosis of the jaw.
The edition also contains a quarterly summary of health professional and consumer advisories.
The October 2014 edition of CARN is available on Health Canada's website at: Canadian Adverse Reaction Newsletter
Media Inquiries:
Media Relations
Health Canada
613-957-2983
